There are currently 472 clinical trials in Kansas City, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kansas Medical Center, University of Kansas Cancer Center, Kansas University Medical Center and Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022
Recruiting
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Prostate Cancer
Register for Updates
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Recruiting
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Kansas Cancer Center-West, Kansas City, Kansas +1 locations
Conditions: Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Register for Updates
Study of CYR-064 Versus Placebo in Patients.
NCT06019000
Recruiting
Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/30/2024
Locations: KU Medical Center-University of Kansas, Kansas City, Kansas
Conditions: Hyposmia
Register for Updates
Guided Episodic Future Thinking to Increase Physical Activity Adherence and Promote Healthy Brain Aging
NCT06123182
Recruiting
The goal of this behavioral clinical trial is to learn how to increase physical activity in mid-life adults. Specifically, can guided imagery that includes creating mental pictures increase excitement about working out. Participants will be asked to complete testing at the beginning of the study, following 6-weeks of an in-person exercise program, and 6-weeks after finishing the exercise program. Testing will include an exercise test, MRI, questionnaires, computer tasks, and a blood draw.
Gender:
All
Ages:
Between 45 years and 65 years
Trial Updated:
04/30/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Exercise Training, Aging
Register for Updates
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)
NCT03981289
Recruiting
Limb Girdle Muscular Dystrophy comprise a group of disorders made up of over 30 mutations which share a common phenotype of progressive weakness of the shoulder and hip girdle muscles. While the individual genetic mutations are rare, as a cohort, LGMDs are one of the four most common muscular dystrophies. The overall goal of project 1 is to define the key phenotypes as measured by standard clinical outcome assessments (COAs) for limb girdle muscular dystrophies (LGMD) to hasten therapeutic devel... Read More
Gender:
All
Ages:
Between 4 years and 65 years
Trial Updated:
04/29/2024
Locations: Kansas University Medical Center, Kansas City, Kansas
Conditions: Limb Girdle Muscular Dystrophy, Muscular Dystrophies
Register for Updates
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
NCT03981575
Recruiting
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogen... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/29/2024
Locations: Kansas University Medical Center, Kansas City, Kansas
Conditions: Myotonic Dystrophy 1
Register for Updates
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351
Recruiting
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: University of Kansas Medical Center (KUMC), Kansas City, Kansas
Conditions: Severe Hypertriglyceridemia
Register for Updates
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
NCT06397677
Recruiting
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/29/2024
Locations: University of Kansas, Kansas City, Kansas
Conditions: Rheumatoid Arthritis, Interstitial Lung Disease
Register for Updates
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591
Recruiting
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: University of Kansas, Kansas City, Kansas
Conditions: Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Register for Updates
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
NCT05685004
Recruiting
This randomized study is designed to compare the combination of TVI-Brain-1 immunotherapy and standard therapy compared to standard therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after surgery are combined into a vaccine to produce an immune response that significantly increases the number of cancer neoantigen-specific effector T cell precursors in the patient's body. These cancer neoantigen-specific T cells are... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/29/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Glioblastoma Multiforme of Brain
Register for Updates
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612
Recruiting
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: AMR Kansas City Oncology, Kansas City, Kansas
Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Register for Updates
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214
Recruiting
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: University of Kansas Medical Center ., Kansas City, Kansas
Conditions: Sjogren Syndrome
Register for Updates